FINWIRES · TerminalLIVE
FINWIRES

$KURA

6 stories mentioning KURAUpdated 19d ago

Every FINWIRES story that references KURA, newest first.

What's the latest news on KURA?

Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In sector news, the US Department of Health and Human Services is planning to create two deputy commissioner roles at the Food and Drug Administration to focus on technology and drugs, respectively, CNBC reported Tuesday. Specifically, the technology deputy commissioner role would focus on the intersection of health and AI, the report said. HHS officials would appoint the new deputies in what some within the Trump administration view as an attempt to wield greater influence over the agency, CNBC reported.In corporate news, McKesson (MCK) agreed to buy Precision Medicine Group for $2.25 billion as part of the drug distributor's efforts to boost its clinical research and commercialization services. McKesson shares rose 3.1%.Anavex Life Sciences (AVXL) shares surged 14% after the company's fiscal Q3 swung to profits.Kura Oncology (KURA) shares jumped past 9% in Tuesday trading, a day after a regulatory filing showed CEO Troy Wilson purchased 100,000 shares at a weighted average price of $12.39.Jazz Pharmaceuticals (JAZZ) shares added 1.8% after the company said the US Food and Drug Administration approved two of its Ziihera-containing regimens to treat adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of cancer.

$AVXL$JAZZ$KURA$MCK
Sectors

Sector Update: Healthcare

Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In corporate news, Kura Oncology (KURA) shares jumped past 10% in Tuesday trading, a day after a regulatory filing showed CEO Troy Wilson purchased 100,000 shares at a weighted average price of $12.39.

$KURA
Wire

Kura Oncology Shares Rise After CEO Purchases 100,000 Shares

Kura Oncology (KURA) stock rose 9.5% in Tuesday trading, a day after a regulatory filing showed CEO Troy Wilson purchased 100,000 shares at a weighted average price of $12.39.Price: $13.58, Change: $+1.18, Percent Change: +9.48%

$KURA
Sectors

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) gained 1.6%.In corporate news, Abbott Laboratories' (ABT) end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a note. Abbott shares rose 1.7%.Merck (MRK) shares added 2.8% after it said Friday that the European Commission has approved Enflonsia to prevent respiratory tract disease in newborns and infants.Kura Oncology (KURA) shares jumped past 9% after it said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.Psyence Biomedical (PBM) shares surged 30% after it acknowledged recent reports saying that the US administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. Through its investment in PsyLabs, Psyence has established a position in the manufacturing of ibogaine and ibogaine derivatives, it said.

$ABT$KURA$MRK$PBM
Sectors

Sector Update: Health Care Stocks Higher Friday Afternoon

Health care stocks climbed Friday afternoon, with the NYSE Health Care Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) advanced 1.4%.In corporate news, Merck (MRK) shares rose 2.3% after it said Friday that the European Commission has approved Enflonsia to prevent respiratory tract disease in newborns and infants.Kura Oncology (KURA) shares jumped nearly 7% after it said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.Psyence Biomedical (PBM) shares surged 66% after it acknowledged recent reports saying that the US administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. Through its investment in PsyLabs, Psyence has established a position in the manufacturing of ibogaine and ibogaine derivatives, it said.

$KURA$MRK$PBM
Sectors

Sector Update: Health Care Stocks Higher Pre-Bell Friday

Health care stocks were higher before Friday's opening bell, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.5% and the iShares Biotechnology ETF (IBB) advancing 0.2%.Trevi Therapeutics (TRVI) shares were down more than 6% before market open. The company said late Thursday it priced its public offering of 11.6 million common shares at $13 each for about $150 million in gross proceeds.Gilead Sciences (GILD) said Friday it has received all the regulatory approvals required for its previously announced acquisition of Arcellx. The company's shares were nearly 1% higher.Kura Oncology (KURA) stock rose 8% before market open after the company said that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.

$GILD$IBB$KURA$TRVI$XLV

Track with the FINWIRES app suite